temozolomide has been researched along with tram 34 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butz, L; Dittmann, K; Huber, SM; Klumpp, L; Ruth, P; Stegen, B; Zips, D | 1 |
| Catalano, M; Chece, G; D'Alessandro, G; Di Angelantonio, S; Esposito, V; Grimaldi, A; Limatola, C; Mainiero, F; Porzia, A; Ragozzino, D; Salvati, M; Santoro, A; Wulff, H | 1 |
2 other study(ies) available for temozolomide and tram 34
| Article | Year |
|---|---|
Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells.
Topics: Animals; Calcium; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; G2 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Glioblastoma; Glioma; Histones; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Mice; Potassium Channel Blockers; Pyrazoles; Radiation-Sensitizing Agents; RNA, Messenger; Signal Transduction; Temozolomide | 2015 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Drug Therapy, Combination; G2 Phase Cell Cycle Checkpoints; Glioma; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Kaplan-Meier Estimate; Mice; Mice, Inbred C57BL; Microglia; Neoplasms, Experimental; Neoplastic Stem Cells; Phosphorylation; Primary Cell Culture; Pyrazoles; Temozolomide | 2016 |